Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 289

1.

Acetaminophen, a centrally-acting analgesic involving the periaqueductal grey.

Barrière DA, Boumezbeur F, Dalman R, Cadeddu R, Richard D, Pinguet J, Daulhac L, Sarret P, Whittingstall K, Keller M, Mériaux S, Eschalier A, Mallet C.

Br J Pharmacol. 2019 Nov 16. doi: 10.1111/bph.14934. [Epub ahead of print]

PMID:
31734950
2.

Risk assessment of using off-label morphine sulfate in a population-based retrospective cohort of opioid-dependent patients.

Bertin C, Delorme J, Riquelme M, Peyrière H, Brousse G, Eschalier A, Ardid D, Chenaf C, Authier N.

Br J Clin Pharmacol. 2019 Aug 6. doi: 10.1111/bcp.14082. [Epub ahead of print]

PMID:
31389036
3.

The Peptide ERα17p Is a GPER Inverse Agonist that Exerts Antiproliferative Effects in Breast Cancer Cells.

Lappano R, Mallet C, Rizzuti B, Grande F, Galli GR, Byrne C, Broutin I, Boudieu L, Eschalier A, Jacquot Y, Maggiolini M.

Cells. 2019 Jun 14;8(6). pii: E590. doi: 10.3390/cells8060590.

4.

Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup.

Kerckhove N, Busserolles J, Stanbury T, Pereira B, Plence V, Bonnetain F, Krakowski I, Eschalier A, Pezet D, Balayssac D.

BMJ Open. 2019 Jun 9;9(6):e027770. doi: 10.1136/bmjopen-2018-027770.

5.

Inhibition of Cav 3.2 calcium channels: A new target for colonic hypersensitivity associated with low-grade inflammation.

Picard E, Carvalho FA, Agosti F, Bourinet E, Ardid D, Eschalier A, Daulhac L, Mallet C.

Br J Pharmacol. 2019 Apr;176(7):950-963. doi: 10.1111/bph.14608. Epub 2019 Mar 11.

PMID:
30714145
6.

Chronic Pain Opioid-Maintained Patients Receive Less Analgesic Opioid Prescriptions.

Delorme J, Chenaf C, Bertin C, Riquelme M, Eschalier A, Ardid D, Authier N.

Front Psychiatry. 2018 Jul 23;9:335. doi: 10.3389/fpsyt.2018.00335. eCollection 2018.

7.

Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin.

Poupon L, Lamoine S, Pereira V, Barriere DA, Lolignier S, Giraudet F, Aissouni Y, Meleine M, Prival L, Richard D, Kerckhove N, Authier N, Balayssac D, Eschalier A, Lazdunski M, Busserolles J.

Neuropharmacology. 2018 Sep 15;140:43-61. doi: 10.1016/j.neuropharm.2018.07.026. Epub 2018 Jul 26.

PMID:
30056126
8.

Prescription opioid analgesic use in France: Trends and impact on morbidity-mortality.

Chenaf C, Kaboré JL, Delorme J, Pereira B, Mulliez A, Zenut M, Delage N, Ardid D, Eschalier A, Authier N.

Eur J Pain. 2019 Jan;23(1):124-134. doi: 10.1002/ejp.1291. Epub 2018 Aug 20.

PMID:
30051548
9.

Prevalence of chronic pain with or without neuropathic characteristics in France using the capture-recapture method: a population-based study.

Chenaf C, Delorme J, Delage N, Ardid D, Eschalier A, Authier N.

Pain. 2018 Nov;159(11):2394-2402. doi: 10.1097/j.pain.0000000000001347.

PMID:
30028790
10.

Efficacy and safety of a T-type calcium channel blocker in patients with neuropathic pain: A proof-of-concept, randomized, double-blind and controlled trial.

Kerckhove N, Pereira B, Soriot-Thomas S, Alchaar H, Deleens R, Hieng VS, Serra E, Lanteri-Minet M, Arcagni P, Picard P, Lefebvre-Kuntz D, Maindet C, Mick G, Balp L, Lucas C, Creach C, Letellier M, Martinez V, Navez M, Delbrouck D, Kuhn E, Piquet E, Bozzolo E, Brosse C, Lietar B, Marcaillou F, Hamdani A, Leroux-Bromberg N, Perier Y, Vergne-Salle P, Gov C, Delage N, Gillet D, Romettino S, Richard D, Mallet C, Bernard L, Lambert C, Dubray C, Duale C, Eschalier A.

Eur J Pain. 2018 Aug;22(7):1321-1330. doi: 10.1002/ejp.1221. Epub 2018 Apr 18.

PMID:
29577519
11.

Effect of Optimization of Medical Treatment on Long-Term Survival of Patients With Heart Failure After Implantable Cardioverter Defibrillator and Cardiac Resynchronization Device Implantation (from the French National EGB Database).

Massoullié G, Chouki C, Mulliez A, Rossignol P, Ploux S, Pereira B, Reuillard A, Jean F, Andronache M, Eschalier A, Motreff P, Clerfond G, Bordachar P, Authier N, Eschalier R.

Am J Cardiol. 2018 Mar 15;121(6):725-730. doi: 10.1016/j.amjcard.2017.12.013. Epub 2018 Jan 3.

PMID:
29402420
12.

Effects of S 38093, an antagonist/inverse agonist of histamine H3 receptors, in models of neuropathic pain in rats.

Chaumette T, Chapuy E, Berrocoso E, Llorca-Torralba M, Bravo L, Mico JA, Chalus M, Eschalier A, Ardid D, Marchand F, Sors A.

Eur J Pain. 2018 Jan;22(1):127-141. doi: 10.1002/ejp.1097. Epub 2017 Sep 6.

PMID:
28877402
13.

Disruption of 5-HT2A-PDZ protein interaction differently affects the analgesic efficacy of SSRI, SNRI and TCA in the treatment of traumatic neuropathic pain in rats.

Wattiez AS, Dupuis A, Privat AM, Chalus M, Chapuy E, Aissouni Y, Eschalier A, Courteix C.

Neuropharmacology. 2017 Oct;125:308-318. doi: 10.1016/j.neuropharm.2017.07.034. Epub 2017 Aug 2.

PMID:
28780039
14.

L-Arginine supplementation prevents allodynia and hyperalgesia in painful diabetic neuropathic rats by normalizing plasma nitric oxide concentration and increasing plasma agmatine concentration.

Rondón LJ, Farges MC, Davin N, Sion B, Privat AM, Vasson MP, Eschalier A, Courteix C.

Eur J Nutr. 2018 Oct;57(7):2353-2363. doi: 10.1007/s00394-017-1508-x. Epub 2017 Jul 19.

PMID:
28725942
15.

Acid-Sensing Ion Channel 1a in the amygdala is involved in pain and anxiety-related behaviours associated with arthritis.

Aissouni Y, El Guerrab A, Hamieh AM, Ferrier J, Chalus M, Lemaire D, Grégoire S, Etienne M, Eschalier A, Ardid D, Lingueglia E, Marchand F.

Sci Rep. 2017 Mar 2;7:43617. doi: 10.1038/srep43617.

16.

Development of the First Two-Pore Domain Potassium Channel TWIK-Related K+ Channel 1-Selective Agonist Possessing in Vivo Antinociceptive Activity.

Vivier D, Soussia IB, Rodrigues N, Lolignier S, Devilliers M, Chatelain FC, Prival L, Chapuy E, Bourdier G, Bennis K, Lesage F, Eschalier A, Busserolles J, Ducki S.

J Med Chem. 2017 Feb 9;60(3):1076-1088. doi: 10.1021/acs.jmedchem.6b01285. Epub 2017 Jan 20.

PMID:
28051863
17.
18.

Agomelatine: a new opportunity to reduce neuropathic pain-preclinical evidence.

Chenaf C, Chapuy E, Libert F, Marchand F, Courteix C, Bertrand M, Gabriel C, Mocaër E, Eschalier A, Authier N.

Pain. 2017 Jan;158(1):149-160.

PMID:
27984527
19.

[Therapeutic drug monitoring of olanzapine].

Djerada Z, Brousse G, Niel P, Llorca PM, Eschalier A, Bentue-Ferrer D, Libert F; groupe suivi thérapeutique pharmacologique de la Société française de pharmacologie et de thérapeutique.

Therapie. 2016 Oct 25. pii: S0040-5957(16)30042-7. doi: 10.2515/therapie/2015040. [Epub ahead of print] French.

PMID:
27793422
20.

[Therapeutic drug monitoring of clozapine].

Djerada Z, Daviet F, Llorca PM, Eschalier A, Saint-Marcoux F, Bentué-Ferrer D, Libert F; Groupe suivi thérapeutique pharmacologique de la Société française de pharmacologie et de thérapeutique.

Therapie. 2016 Aug 24. pii: S0040-5957(16)31132-5. doi: 10.2515/therapie/2015041. [Epub ahead of print] French.

PMID:
27771104
21.

Increasing spinal 5-HT2A receptor responsiveness mediates anti-allodynic effect and potentiates fluoxetine efficacy in neuropathic rats. Evidence for GABA release.

Dupuis A, Wattiez AS, Pinguet J, Richard D, Libert F, Chalus M, Aissouni Y, Sion B, Ardid D, Marin P, Eschalier A, Courteix C.

Pharmacol Res. 2017 Apr;118:93-103. doi: 10.1016/j.phrs.2016.09.021. Epub 2016 Sep 20.

PMID:
27663259
22.

Pharmacogenomics in pain treatment.

Peiró AM, Planelles B, Juhasz G, Bagdy G, Libert F, Eschalier A, Busserolles J, Sperlagh B, Llerena A.

Drug Metab Pers Ther. 2016 Sep 1;31(3):131-42. doi: 10.1515/dmpt-2016-0005. Review.

PMID:
27662648
23.

Comparative effects of α2δ-1 ligands in mouse models of colonic hypersensitivity.

Meleine M, Boudieu L, Gelot A, Muller E, Lashermes A, Matricon J, Silberberg C, Theodorou V, Eschalier A, Ardid D, Carvalho FA.

World J Gastroenterol. 2016 Aug 21;22(31):7111-23. doi: 10.3748/wjg.v22.i31.7111.

24.

Codeine Shopping Behavior in a Retrospective Cohort of Chronic Noncancer Pain Patients: Incidence and Risk Factors.

Chenaf C, Kabore JL, Delorme J, Pereira B, Mulliez A, Roche L, Eschalier A, Delage N, Authier N.

J Pain. 2016 Dec;17(12):1291-1301. doi: 10.1016/j.jpain.2016.08.010. Epub 2016 Sep 2.

PMID:
27592608
25.

Therapeutic drug monitoring and tyrosine kinase inhibitors.

Herviou P, Thivat E, Richard D, Roche L, Dohou J, Pouget M, Eschalier A, Durando X, Authier N.

Oncol Lett. 2016 Aug;12(2):1223-1232. Epub 2016 Jun 24.

26.

Incidence of tramadol shopping behavior in a retrospective cohort of chronic non-cancer pain patients in France.

Chenaf C, Kabore JL, Delorme J, Pereira B, Mulliez A, Roche L, Eschalier A, Delage N, Authier N.

Pharmacoepidemiol Drug Saf. 2016 Sep;25(9):1088-98. doi: 10.1002/pds.4056. Epub 2016 Jun 30.

PMID:
27363310
27.

Prognosis and management of myocardial infarction: Comparisons between the French FAST-MI 2010 registry and the French public health database.

Massoullié G, Wintzer-Wehekind J, Chenaf C, Mulliez A, Pereira B, Authier N, Eschalier A, Clerfond G, Souteyrand G, Tabassome S, Danchin N, Citron B, Lusson JR, Puymirat É, Motreff P, Eschalier R.

Arch Cardiovasc Dis. 2016 May;109(5):303-10. doi: 10.1016/j.acvd.2016.01.012. Epub 2016 Apr 20.

28.

[The Nav1.9 channel is crucial for sensing noxious cold].

Lolignier S, Eschalier A, Bonnet C, Delmas P, Busserolles J.

Med Sci (Paris). 2016 Feb;32(2):162-5. doi: 10.1051/medsci/20163202009. Epub 2016 Mar 2. French. No abstract available.

29.

Fully automated semi-quantitative toxicological screening in three biological matrices using turbulent flow chromatography/high resolution mass spectrometry.

Roche L, Pinguet J, Herviou P, Libert F, Chenaf C, Eschalier A, Authier N, Richard D.

Clin Chim Acta. 2016 Apr 1;455:46-54. doi: 10.1016/j.cca.2016.01.017. Epub 2016 Jan 23.

PMID:
26812390
30.

Potassium channels in neuropathic pain: advances, challenges, and emerging ideas.

Busserolles J, Tsantoulas C, Eschalier A, López García JA.

Pain. 2016 Feb;157 Suppl 1:S7-14. doi: 10.1097/j.pain.0000000000000368. Review.

PMID:
26785158
31.

Anti-nociceptive effect of Faecalibacterium prausnitzii in non-inflammatory IBS-like models.

Miquel S, Martín R, Lashermes A, Gillet M, Meleine M, Gelot A, Eschalier A, Ardid D, Bermúdez-Humarán LG, Sokol H, Thomas M, Theodorou V, Langella P, Carvalho FA.

Sci Rep. 2016 Jan 18;6:19399. doi: 10.1038/srep19399.

32.

Cholinergic Neurotransmission in the Posterior Insular Cortex Is Altered in Preclinical Models of Neuropathic Pain: Key Role of Muscarinic M2 Receptors in Donepezil-Induced Antinociception.

Ferrier J, Bayet-Robert M, Dalmann R, El Guerrab A, Aissouni Y, Graveron-Demilly D, Chalus M, Pinguet J, Eschalier A, Richard D, Daulhac L, Marchand F, Balayssac D.

J Neurosci. 2015 Dec 16;35(50):16418-30. doi: 10.1523/JNEUROSCI.1537-15.2015.

33.

Determination of irinotecan and SN38 in human plasma by TurboFlow™ liquid chromatography-tandem mass spectrometry.

Herviou P, Richard D, Roche L, Pinguet J, Libert F, Eschalier A, Durando X, Authier N.

J Pharm Biomed Anal. 2016 Jan 25;118:284-291. doi: 10.1016/j.jpba.2015.10.044. Epub 2015 Nov 4.

PMID:
26580826
34.

Analgesic effects of mambalgin peptide inhibitors of acid-sensing ion channels in inflammatory and neuropathic pain.

Diochot S, Alloui A, Rodrigues P, Dauvois M, Friend V, Aissouni Y, Eschalier A, Lingueglia E, Baron A.

Pain. 2016 Mar;157(3):552-9. doi: 10.1097/j.pain.0000000000000397.

PMID:
26492527
35.

[Therapeutic Drug Monitoring of Clozapine].

Djerada Z, Daviet F, Llorca PM, Eschalier A, Saint-Marcoux F, Bentué-Ferrer D, Libert F.

Therapie. 2015 Jul 28. [Epub ahead of print] French.

PMID:
26220922
36.

[Therapeutic Drug Monitoring of Olanzapine].

Djerada Z, Brousse G, Niel P, Llorca PM, Eschalier A, Bentue-Ferrer D, Libert F.

Therapie. 2015 Jul 28. [Epub ahead of print] French.

PMID:
26220921
37.

The Nav1.9 channel is a key determinant of cold pain sensation and cold allodynia.

Lolignier S, Bonnet C, Gaudioso C, Noël J, Ruel J, Amsalem M, Ferrier J, Rodat-Despoix L, Bouvier V, Aissouni Y, Prival L, Chapuy E, Padilla F, Eschalier A, Delmas P, Busserolles J.

Cell Rep. 2015 May 19;11(7):1067-78. doi: 10.1016/j.celrep.2015.04.027. Epub 2015 May 7.

38.

99mTc-NTP 15-5 Imaging for Cartilage Involvement in Experimental Rheumatoid Arthritis: Comparison with Routinely Used Molecular Imaging Methods and Sensitivity to Chronic Nonsteroidal Antiinflammatory Drug Treatment.

Khairnar A, Marchand F, Vidal A, Etienne M, Miladi I, Auzeloux P, Cachin F, Eschalier A, Chezal JM, Ardid D, Miot-Noirault E.

J Nucl Med. 2015 May;56(5):798-804. doi: 10.2967/jnumed.114.151415. Epub 2015 Apr 3.

39.

Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet-NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial.

Balayssac D, Ferrier J, Pereira B, Gillet B, Pétorin C, Vein J, Libert F, Eschalier A, Pezet D.

BMJ Open. 2015 Apr 1;5(4):e007479. doi: 10.1136/bmjopen-2014-007479.

40.

Impact of clinical characteristics and management on the prognosis of unselected heart failure patients.

Eschalier R, Chenaf C, Mulliez A, Yalioua A, Clerfond G, Authier N, Vorilhon C, Citron B, Pereira B, Jean F, Souteyrand G, Motreff P, Eschalier A, Lusson JR.

Cardiovasc Drugs Ther. 2015 Feb;29(1):89-98. doi: 10.1007/s10557-015-6572-y.

PMID:
25700624
41.

Heart failure prognosis and management in over-80-year-old patients: data from a French national observational retrospective cohort.

Vorilhon C, Chenaf C, Mulliez A, Pereira B, Clerfond G, Authier N, Jean F, Motreff P, Citron B, Eschalier A, Lusson JR, Eschalier R.

Eur J Clin Pharmacol. 2015 Feb;71(2):251-60. doi: 10.1007/s00228-014-1794-7. Epub 2014 Dec 24.

PMID:
25537794
42.

Supra-spinal FAAH is required for the analgesic action of paracetamol in an inflammatory context.

Dalmann R, Daulhac L, Antri M, Eschalier A, Mallet C.

Neuropharmacology. 2015 Apr;91:63-70. doi: 10.1016/j.neuropharm.2014.11.006. Epub 2014 Nov 21.

PMID:
25448494
43.

[Tribute to professor Pierre Duchene-Marullaz (1921-2014)].

Eschalier A, Montastruc JL.

Therapie. 2014 Nov-Dec;69(6):479. doi: 10.2515/therapie/2014061. Epub 2014 Oct 16. French. No abstract available.

44.

Role of the TREK2 potassium channel in cold and warm thermosensation and in pain perception.

Pereira V, Busserolles J, Christin M, Devilliers M, Poupon L, Legha W, Alloui A, Aissouni Y, Bourinet E, Lesage F, Eschalier A, Lazdunski M, Noël J.

Pain. 2014 Dec;155(12):2534-44. doi: 10.1016/j.pain.2014.09.013. Epub 2014 Sep 18.

PMID:
25239074
45.

Low doses of dextromethorphan have a beneficial effect in the treatment of neuropathic pain.

Morel V, Pickering G, Etienne M, Dupuis A, Privat AM, Chalus M, Eschalier A, Daulhac L.

Fundam Clin Pharmacol. 2014 Dec;28(6):671-80. doi: 10.1111/fcp.12076. Epub 2014 Apr 30.

PMID:
24702319
46.

T-type calcium channels in chronic pain: mouse models and specific blockers.

François A, Laffray S, Pizzoccaro A, Eschalier A, Bourinet E.

Pflugers Arch. 2014 Apr;466(4):707-17. doi: 10.1007/s00424-014-1484-4. Epub 2014 Mar 4. Review.

PMID:
24590509
47.

Synthesis and structure-activity relationship study of substituted caffeate esters as antinociceptive agents modulating the TREK-1 channel.

Rodrigues N, Bennis K, Vivier D, Pereira V, C Chatelain F, Chapuy E, Deokar H, Busserolles J, Lesage F, Eschalier A, Ducki S.

Eur J Med Chem. 2014 Mar 21;75:391-402. doi: 10.1016/j.ejmech.2014.01.049. Epub 2014 Jan 31.

PMID:
24561669
48.

Assessment of thermal sensitivity in rats using the thermal place preference test: description and application in the study of oxaliplatin-induced acute thermal hypersensitivity and inflammatory pain models.

Balayssac D, Ling B, Ferrier J, Pereira B, Eschalier A, Authier N.

Behav Pharmacol. 2014 Apr;25(2):99-111. doi: 10.1097/FBP.0000000000000026.

PMID:
24525711
49.

Ca(v)3.2 calcium channels: the key protagonist in the supraspinal effect of paracetamol.

Kerckhove N, Mallet C, François A, Boudes M, Chemin J, Voets T, Bourinet E, Alloui A, Eschalier A.

Pain. 2014 Apr;155(4):764-72. doi: 10.1016/j.pain.2014.01.015. Epub 2014 Jan 18.

PMID:
24447516
50.

Activation of TREK-1 by morphine results in analgesia without adverse side effects.

Devilliers M, Busserolles J, Lolignier S, Deval E, Pereira V, Alloui A, Christin M, Mazet B, Delmas P, Noel J, Lazdunski M, Eschalier A.

Nat Commun. 2013;4:2941. doi: 10.1038/ncomms3941.

PMID:
24346231

Supplemental Content

Loading ...
Support Center